Matinas BioPharma Holdings, Inc. (MTNB) Stock Price, Quote & News - Stock Analysis (2024)

About MTNB Financial Performance Analyst Forecast News Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024 Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024 Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024 Matinas BioPharma Prices $10 Million Registered Direct Offering Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model Top trending biotech stocks: ANVS, MTNB, AVTX, TPST Patient with Candida krusei Infection in Matinas BioPharma's Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution Matinas BioPharma to Present at Two Investment Conferences in October 2023 Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases Matinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023 Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023 Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023 References